Hemodynamic Challenges in Critically Ill Patients with Cirrhosis

Cirrhosis profoundly alters cardiovascular physiology, creating unique challenges in diagnosis and treatment circulatory shock. In patients with advanced liver disease, portal hypertension, splanchnic vasodilation, and hyperdynamic circulation reduce effective arterial blood volume, while cirrhotic cardiomyopathy limits cardiac reserve. Together, these changes complicate hemodynamic assessment and undermine the applicability of standard sepsis algorithms. Conventional markers of shock, including targeted mean arterial pressure and serum lactate levels, can be misleading because cirrhotic patients often tolerate lower baseline pressures and exhibit impaired lactate clearance. Fluid resuscitation carries a high risk of volume overload; albumin has demonstrated improvements in short-term hemodynamic parameters but not consistent survival benefits. Norepinephrine is the first-line vasopressor, while vasopressin analogues are considered in refractory cases or when hepatorenal physiology predominates. Emerging tools such as bedside ultrasound and the Venous Excess Ultrasound (VExUS) score may aid in differentiating hypovolemia from venous congestion. Acute-on-chronic liver failure, frequently precipitated by infection, exemplifies the complex interplay of systemic inflammation, circulatory collapse, and multiorgan failure in this population. Optimal management therefore requires an individualized, physiology-driven approach emphasizing cautious fluid administration, tailored vasopressor use, and serial assessment of tissue perfusion. Future trials focused on cirrhotic populations are essential to refine resuscitation targets and improve survival outcomes.